US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

AI Healthcare

619.81

+51.028.97%

Number of Gainers:4

Number of Losers:- -

Number of Flat:- -

PE:- -

High:626.14

Open:571.03

Low:571.03

Close:568.79

Loading ...

Tempus AI Shares Extend Losses, Last Down 14.8%

THOMSON REUTERS

BRIEF-Spruce Point Capital Management Announces Investment Opinion

Tempus AI Stock Sinks 10% Following Spruce Point Short Report

THOMSON REUTERS

Spruce Point short Tempus AI, sees 50%-60% potential downside risk

Spruce Point Capital Issues Strong Sell Opinion on Tempus AI, Citing Concerns Over AI Capabilities and Financial Practices

Spruce Point: Short Position in Tempus AI

THOMSON REUTERS

Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on Tempus AI, Inc. (Nasdaq: Tem)

THOMSON REUTERS

Tempus AI Inc. Celebrates a Decade of Discovery with 1,500 Research Projects Advancing Precision Medicine

Ambry Genetics, a Tempus AI Subsidiary, Enhances Rare Disease Diagnosis with Proactive Exome Reanalysis

3 Monster Stocks to Hold for the Next 10 Years

Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4611/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4611","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","market":"US","secType":"PLATE","nameCN":"AI Healthcare","latestPrice":619.81287,"timestamp":1749239999999,"preClose":568.7886,"halted":0,"volume":80607447,"delay":0,"changeRate":0.089707,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":51.024292,"latestTime":"06-06 16:00:00 EDT","open":571.0336,"high":626.13544,"low":571.0336,"amount":1306537605.096571,"amplitude":0.096876,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.036362,"peRate":-8.266372,"turnoverRate":0.121041,"increases":4,"decrements":0,"flats":0,"marketCap":18454890496,"floatMarketCap":13646941824},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","high":626.13544,"amplitude":0.096876,"preClose":568.7886,"low":571.0336,"pbRate":"4.036362","latestPrice":619.81287,"volume":80607447,"delay":0,"open":571.0336,"prevYearClose":530.4984,"prevWeekClose":532.1039,"prevMonthClose":532.1039,"prevQuarterClose":527.803,"fiveDayClose":532.1039,"twentyDayClose":587.4983,"sixtyDayClose":594.3155,"secType":"PLATE","market":"US","turnoverRate":0.121041,"peRate":-8.266372,"marketCap":18454890496,"floatMarketCap":13646941824,"timestamp":1749239999999,"nameCN":"AI Healthcare"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4611\",,,,undefined,":{"bkCode":"BK4611","up":4,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4611\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2538247786","title":"Tempus AI Shares Extend Losses, Last Down 14.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2538247786","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538247786?lang=en_us&edition=fundamental","pubTime":"2025-05-28 23:07","pubTimestamp":1748444833,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"5a1f935a527245ffb5153fe5b9fa56eb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nL3N3S016R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4611","LU1861558580.USD","TEM","BK4613","BK4121","LU1861559042.SGD"],"gpt_icon":0},{"id":"2538472198","title":"BRIEF-Spruce Point Capital Management Announces Investment Opinion","url":"https://stock-news.laohu8.com/highlight/detail?id=2538472198","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538472198?lang=en_us&edition=fundamental","pubTime":"2025-05-28 22:48","pubTimestamp":1748443735,"startTime":"0","endTime":"0","summary":"BRIEF-Spruce Point Capital Management Announces Investment OpinionMay 28 (Reuters) - Tempus AI Inc TEM.O:SPRUCE POINT CAPITAL MANAGEMENT ANNOUNCES INVESTMENT OPINION: RELEASES REPORT AND STRONG SELL R","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nFWN3S00OP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4613","BK4611","TEM","LU1861558580.USD","LU1861559042.SGD","BK4121"],"gpt_icon":0},{"id":"2538471582","title":"Tempus AI Stock Sinks 10% Following Spruce Point Short Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2538471582","media":"THOMSON REUTERS","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538471582?lang=en_us&edition=fundamental","pubTime":"2025-05-28 21:32","pubTimestamp":1748439149,"startTime":"0","endTime":"0","summary":"","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"87c67b372524a137759a6193f888782b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nL3N3S012L:1","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Tempus AI Stock Sinks 10% Following Spruce Point Short Report","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","LU1861559042.SGD","BK4613","BK4611","LU1861558580.USD","TEM"],"gpt_icon":0},{"id":"2538792774","title":"Spruce Point short Tempus AI, sees 50%-60% potential downside risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2538792774","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538792774?lang=en_us&edition=fundamental","pubTime":"2025-05-28 21:15","pubTimestamp":1748438109,"startTime":"0","endTime":"0","summary":"Spruce Point Capital Management issued a report entitled, “The Tempest Surrounding Tempus AI (TEM)”, that outlines why the firm believes and estima...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spruce-point-short-tempus-ai-sees-50-60-potential-downside-risk-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":"87c67b372524a137759a6193f888782b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spruce-point-short-tempus-ai-sees-50-60-potential-downside-risk-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","TEM","LU1861559042.SGD","BK4611","BK4613","LU1861558580.USD"],"gpt_icon":0},{"id":"2538796014","title":"Spruce Point Capital Issues Strong Sell Opinion on Tempus AI, Citing Concerns Over AI Capabilities and Financial Practices","url":"https://stock-news.laohu8.com/highlight/detail?id=2538796014","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538796014?lang=en_us&edition=fundamental","pubTime":"2025-05-28 21:10","pubTimestamp":1748437822,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire  on May 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"87c67b372524a137759a6193f888782b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL2XvY41:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","BK4611","LU1861558580.USD","BK4121","BK4613","TEM"],"gpt_icon":1},{"id":"2538479993","title":"Spruce Point: Short Position in Tempus AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2538479993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538479993?lang=en_us&edition=fundamental","pubTime":"2025-05-28 21:10","pubTimestamp":1748437816,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"87c67b372524a137759a6193f888782b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nFWN3S00OP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1861559042.SGD","TEM","BK4613","BK4611","LU1861558580.USD","BK4121"],"gpt_icon":0},{"id":"2538347996","title":"Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on Tempus AI, Inc. (Nasdaq: Tem)","url":"https://stock-news.laohu8.com/highlight/detail?id=2538347996","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538347996?lang=en_us&edition=fundamental","pubTime":"2025-05-28 21:10","pubTimestamp":1748437816,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"87c67b372524a137759a6193f888782b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nFWN3S00OP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1861558580.USD","TEM","BK4121","BK4611","BK4613","LU1861559042.SGD"],"gpt_icon":0},{"id":"2538476829","title":"Tempus AI Inc. Celebrates a Decade of Discovery with 1,500 Research Projects Advancing Precision Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2538476829","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538476829?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:30","pubTimestamp":1748435427,"startTime":"0","endTime":"0","summary":"Tempus AI Inc. has announced its involvement in nearly 1,500 research projects over the past decade, marking a significant milestone in its mission to advance precision medicine and improve patient care. Utilizing its AI-powered platform, Tempus has collaborated with top academic institutions, community health systems, and biopharma organizations to propel cutting-edge research. Notably, Tempus has contributed to approximately 1,000 biopharma research projects and nearly 500 provider-led initiatives. Their diagnostic assays have yielded clinically-relevant insights across more than 200 projects. Additionally, Tempus' biological modeling lab has supported around 65 research initiatives, enhancing understanding in therapy selection and drug discovery. These efforts align with Tempus' commitment to delivering data-driven insights that improve patient outcomes and accelerate scientific discovery.Disclaimer: This news brief was created by Public Technologies  using generative artificial int","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDLc6RlyN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4613","LU1861558580.USD","TEM","BK4121","BK4611","LU1861559042.SGD"],"gpt_icon":1},{"id":"2538457035","title":"Ambry Genetics, a Tempus AI Subsidiary, Enhances Rare Disease Diagnosis with Proactive Exome Reanalysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2538457035","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538457035?lang=en_us&edition=fundamental","pubTime":"2025-05-27 18:15","pubTimestamp":1748340914,"startTime":"0","endTime":"0","summary":"Ambry Genetics, a subsidiary of Tempus AI, Inc., has recently published a study in Genetics in Medicine, highlighting the impact of their Patient for Life program on rare disease diagnosis. The program involves the proactive reanalysis of exome test data, leveraging newly discovered gene-disease associations and emerging evidence to reclassify genetic variants. This approach has led to diagnoses in 5% of initially negative or uninformative cases. The program is praised for its potential to transform diagnostic outcomes for patients with rare diseases, providing renewed hope and connecting families with similar experiences. Ambry Genetics emphasizes its commitment to updating clinical reports proactively, ensuring patients benefit from the latest scientific discoveries.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDLcg7q3T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","TEM","BK4613","BK4611","LU1861558580.USD","BK4121"],"gpt_icon":1},{"id":"2538864614","title":"3 Monster Stocks to Hold for the Next 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2538864614","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538864614?lang=en_us&edition=fundamental","pubTime":"2025-05-27 08:05","pubTimestamp":1748304300,"startTime":"0","endTime":"0","summary":"A handful of industries are on the verge of explosive growth. These three companies are poised to gain the most.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/05/26/3-monster-stocks-to-hold-for-the-next-10-years/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["RXRX","BK4609","BK4539","BK4611","BK4139","BK4548"],"gpt_icon":1},{"id":"2538111769","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2538111769","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538111769?lang=en_us&edition=fundamental","pubTime":"2025-05-25 17:03","pubTimestamp":1748163782,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novo Nordisk (NVO – Research Report), Beam Therape...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-novo-nordisk-nvo-beam-therapeutics-beam-and-tscan-therapeutics-tcrx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-novo-nordisk-nvo-beam-therapeutics-beam-and-tscan-therapeutics-tcrx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0154236417.USD","BK4599","BK4539","NVO","HCSG","BK4556","BK4007","IE00BKVL7J92.USD","BEAM","BK4137","BK4532","BK4585","BK4535","TCRX","IE00BZ1G4Q59.USD","BK4505","BK4611","BK4588","LU1093756168.USD","BK4139","LU1093756325.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":51,"code":"91000000","status":"200"}]}}